STX2 and infection: Notably, there is a high interest in developing small-molecule inhibitors of STx2 because antibiotic therapy is contraindicated for treatment of infections caused by STx2-producing Escherichia coli and antidotes are not available (35, 36, 37, 38, 39, 40, 41).